ARTICLE | Product Development
Carisma adds support for CAR macrophage platform with preclinical data
April 12, 2021 9:34 PM UTC
Carisma is boosting confidence in its CAR macrophage platform ahead of its first clinical readout with preclinical data supporting the cell therapy’s differentiated activity against solid tumors.
The company presented a trio of abstracts at the 2021 American Association for Cancer Research (AACR) annual meeting, including one that describes mechanistic details about how CAR macrophages may function against heterogeneous solid tumors. ...
BCIQ Company Profiles
BCIQ Target Profiles
Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)